Effects of Implementing a High Potassium Diet in Heart Failure Patients

Heart Failure Clinical Trial

Official title:

Safety and Physiologic Effects of Implementing a High Potassium Diet in Heart Failure Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03059680
• Other study ID #: MSH 11-0259-A
• Status: Completed
• Phase: N/A
• Start date: January 2012
• Est. completion date: January 2017

Study information

• Verified date: February 2020
• Source: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the safety and physiologic effects of increasing dietary potassium intake in individuals with heart failure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: January 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• All patients classified as having HF, both systolic and diastolic.

• New York Heart Association class II-III symptoms.

• Treatment with an beta blocker, ACE inhibitor, or angiotensin receptor blocker without any adjustment over the previous month

• Intake at baseline of = 3 servings of fruits and vegetables per day. Servings defined by Health Canada's food guide.

Exclusion Criteria:

• Patients with an episode of decompensated heart failure, acute coronary syndrome, or revascularization within the previous 3 months of study inclusion.

• Patients receiving insulin therapy

• Glomerular filtration rate < 40mL/min/1.73 m2

• Pregnancy and lactation (women of childbearing potential will be included but will have to have a negative pregnancy test prior to inclusion).

• Inability to provide informed consent.

Related Conditions & MeSH terms

• Heart Failure

Intervention

Other:
• High potassium diet
An increase in consumption of high potassium fruits and vegetables

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum potassium concentration		10 days and 3 weeks